Article

Prostate cancer assay may help distinguish aggressive vs. indolent disease

A biopsy-based genomic assay that would discriminate between aggressive prostate cancer and indolent disease to guide treatment decisions is under development.

Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
1 expert in this video
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.